Empagliflozin Reduces Weight and Markers of Visceral Adiposity in Type 2 Diabetes

Design and method: Using pooled data from 2477 patients with type 2 diabetes from four 24-week phase III randomised trials of empagliflozin 10 mg or 25 mg (n = 1652) versus placebo (n = 825) as monotherapy or add-on therapy (mean [SD] age 55.6 [10.2] years, HbA1c 8.0 [0.9]%, office SBP 129 [15] mmHg and BMI 28.7 [5.5] kg/m2), we assessed changes from baseline in HbA1c, body weight, validated markers of VA (waist circumference [WC], index of central obesity [ICO; ratio WC/height], visceral adiposity index [VAI; VAImen: (WC/[39.68 + (1.88 × BMI)] × (TG/1.03) × (1.31/HDL)); VAIwomen: (WC/[36.58 + (1.89 × BMI)] × (TG/0.81) × (1.52/HDL)]), and changes in estimated total body fat (eTBF) using the YMCA-formula (eTBFmen: 100*[−98.42 + (4.15*WC) – (0.082*weight)]/weight; eTBFwomen:100*[−76.76 + (4.15*WC) – (0.082*weight)]/weight).